# Milestone Scientific Inc.: Form 10-Q for the period ended Sep 30, 2009

- Company: [Milestone Scientific Inc.](/companies/mlss.md) (CIK 855683)
- Form: 10-Q
- Filed: 2009-11-12
- Accepted by EDGAR: Nov 12, 2009, 12:08 ET
- Period: 2009-09-30
- Accession: 0000950123-09-061578
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/855683/000095012309061578/c92409e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/855683/000095012309061578/

## Management's discussion and analysis

As filed, 34,888 characters.

The following discussions of our financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this Form 10-Q. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements. See “Risk Factors” on Part II. ITEM 1A of this Form 10-Q.

### OVERVIEW

During the third quarter of 2009, we remained focused on advancing efforts to achieve our two primary objectives; those being:

- Optimizing our tactical approach to product sales and marketing in order to materially increase penetration of the global dental and medical markets with our proprietary, patented Computer-Controlled Local Anesthesia Delivery (C-CLAD) solution, the *STA Single Tooth Anesthesia System (STA System*); and
- Identifying and pursing strategic collaborations with third parties to jointly develop new products utilizing our patented *CompuFlo* pressure force technology for novel new medical applications.

### STA System Awards — Industry Recognition

Since its market introduction in the spring of 2007, the *STA System* has received rave reviews and awards from the dental industry. In July 2007, noted industry publication *Dentistry Today* featured the *STA System* as one of the “Top 100 Products in 2007,” helping to promote much broader recognition of the instrument and validating the *STA System’*s value proposition for dentists and patients alike. In April 2008, *Medical Device & Diagnostic Industry* magazine distinguished the *STA System* as a 2008 Medical Design Excellence Award winner in the “Dental Instruments, Equipment and Supplies” product category. Of the 33 products to receive this coveted award, the *STA System* was one of only two winning products that serve dental practitioners.

In December 2008, the *STA System* was again recognized as one of the dental industry’s best technological innovations, winning a “Townie Choice Award” from *Dentaltown Magazine* in the category “Anesthetics: Technique System”. This marked the second consecutive year that Milestone won a “Townie Choice Award”; in 2007, we won the same award for our *CompuDent/The Wand.* Also in December 2008, our *STA System* was named as a *Dental Products Report “*Top 100 2008 Product of Distinction”. Each year, *DPR* spotlights the year’s Top 100 products. Of these 100 products, 50 are the ones most often inquired about by *DPR’*s readers via an online and Product Information Card reader service program. The other 50 represent “New Classics,” which recognize both old and newer products and categories chosen by *DPR’s* editorial staff for their “perceived impact on driving innovation or helping to establish a new, higher standard of care for patients.” The *STA System* was recognized as a “New Classic” in the Technology category.

### Second Annual Symposium on C-CLAD

In addition to winning noted acclaim among leading dental publications, our award winning *STA System* has also been gaining the support of many of the world’s leading dental practitioners and key opinion leaders. In February 2008, we hosted the First International C-CLAD Symposium in New Orleans, welcoming a distinguished panel of dental experts who gathered to discuss advancements in the scientific and clinical practice communities toward the common goal of advancing the science, knowledge and art of C-CLAD in dentistry. The forum yielded a number of ideas on how we can integrate the *STA System* not only into dental school curricula, but also extend messaging regarding its many unique benefits to the dental community and patients alike.

On May 1 through 3, 2009, we hosted the Second International Annual Symposium on C-CLAD in Amelia Island, Florida. Stanley Malamed, DDS, Professor of Anesthesia & Medicine at the University of Southern California, School of Dentistry, again served as Chairman of the invitational event. With attendance triple that of 2008, this year’s Symposium covered a broad range of C-CLAD-related topics including:

- The History of C-CLAD
- Treating with Connection
- Heart Rate Study
- *STA* Compassionate Care in the 21st Century
- Injection Advances and Challenges
- Physiologic and Clinical Characteristics of PDL Anesthesia Delivered by a High Pressure Hand piece and a Computerized Device
- The *STA* for Tots and Teens
- Computerized Local Anesthesia in Dentistry: A Review
- Today’s Technology
- Managing a Successful Dental Practice: Why People Keep Coming Back
- *STA —* The Dental School’s Perspective
- Futuristic Vistas: The Dentist/Hygienist Partnership

We expect to publish and broadly distribute more than 100,000 copies of a comprehensive monograph reflecting the topics discussed at the Symposium and a consensus on the attendees’ attitudes, ideas and suggestions relating to promoting global industry adoption of C-CLAD technologies as the new standard of care for administering dental injections.

### STA System Growth

Since its market introduction in early 2007, the *STA System,* a prior computerized controlled local anesthesia delivery product, has been used to deliver tens of millions of safe, effective and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the *STA System* is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide. The utility and value of the *STA System* is perhaps best summarized by Dr. Joe Blaes, who wrote in the December 2008 edition of *Dental Economics, “*I tried the *STA System* and my patients absolutely love it. This is a no brainer — go get one ASAP!”

### Global Distribution Network

The *STA System* and related hand pieces are marketed to the dental industry in the United States and Canada by many of the nation’s leading dental supply companies, including Henry Schein, Inc., Patterson Dental Supply, Benco Dental, Burkhart Dental, Goetze Dental, Atlanta Dental, Darby Dental Supply, Dental Health Products, Nashville Dental and Parkway Dental.

Collectively, our domestic network has more than 2,500 independent sales representatives trained to sell the *STA System* and related hand pieces to dentists throughout North America.

On the global front, we also have granted exclusive marketing and distribution rights for the *STA System* to select dental suppliers in various international regions in Asia, Africa and Europe. They include Istrodent in South Africa and Unident in the Scandinavian countries of Denmark, Sweden, Norway and Iceland.

In April 2009, we signed an Exclusive Distribution and Marketing Agreement with China National Medicines Corporation, d/b/a Sinopharm, which is China’s largest domestic manufacturer, distributor and marketer of pharmaceuticals and importer of medical devices and the country’s largest domestic distributor of dental anesthetic carpules to the Chinese dental industry.

Shortly before the end of the second quarter, we announced that we were refining our international marketing strategy to gain greater access to and penetration of the international dental markets for the *STA System, CompuDent* and related disposable hand pieces. The new sales strategy provides for increasing hands-on oversight and support of our existing international distribution network, while also attracting new distributors throughout Europe, Asia and South America. To assist in this endeavor, Milestone named Shaul Koren, founder and CEO of Istrodent Pty Ltd AB and one of our strongest marketing allies outside of the U.S., as our new International Sales Director. In collaboration with senior management, Mr. Koren will help manage product sales for us in all markets outside of North America.

As a result of growing market awareness and appreciation of the *STA System*, coupled with our active worldwide marketing efforts, sales of the instrument (and related hand pieces) yielded four consecutive quarters of growth in 2008. In the first nine months of this year, we saw no indication that this trend is slowing or reversing. Sales of the *STA System* and related recurring sales from disposable hand pieces helped increase total revenues by $1,380,726 during the nine months ended September 30, 2009, when compared to the same nine month period in the prior year.

### Segmented Sales Performance

The following table shows a breakdown of our product sales (net), domestically and internationally, by product category, and the percentage of product sales (net) by each product category:

| DOMESTIC | Three Months Ended September 30, 2009 |  | 2008 |  |
| --- | ---: | ---: | ---: | ---: |
| Instruments | $263,451 | 22.9% | $365,887 | 27.6% |
| Handpieces | 865,508 | 75.1% | 942,613 | 71.3% |
| Other | 22,516 | 2.0% | 14,165 | 1.1% |
| Total Domestic | $1,151,475 | 100.0% | $1,322,665 | 100.0% |
| **INTERNATIONAL** |  |  |  |  |
| Instruments | $248,080 | 32.7% | $132,992 | 27.1% |
| Handpieces | 507,747 | 67.0% | 355,041 | 72.4% |
| Other | 1,961 | 0.3% | 2,405 | 0.5% |
| Total International | $757,788 | 100.0% | $490,438 | 100.0% |
| **DOMESTIC/INTERNATIONAL ANALYSIS** |  |  |  |  |
| Domestic | $1,151,475 | 60.3% | $1,322,665 | 73.0% |
| International | 757,788 | 39.7% | 490,438 | 27.0% |
| Total Product Sales | $1,909,263 | 100.0% | $1,813,103 | 100.0% |

| DOMESTIC | Nine Months Ended September 30, 2009 |  | 2008 |  |
| --- | ---: | ---: | ---: | ---: |
| Instruments | $1,317,589 | 32.6% | $420,028 | 13.0% |
| Handpieces | 2,659,310 | 65.8% | 2,743,031 | 85.5% |
| Other | 61,407 | 1.6% | 46,625 | 1.5% |
| Total Domestic | $4,038,306 | 100.0% | $3,209,684 | 100.0% |
| **INTERNATIONAL** |  |  |  |  |
| Instruments | $796,064 | 37.7% | $426,530 | 27.8% |
| Handpieces | 1,309,526 | 62.0% | 1,097,692 | 71.7% |
| Other | 7,088 | 0.3% | 8,070 | 0.5% |
| Total International | $2,112,678 | 100.0% | $1,532,292 | 100.0% |
| **DOMESTIC/INTERNATIONAL ANALYSIS** |  |  |  |  |
| Domestic | $4,038,306 | 65.7% | $3,209,684 | 67.7% |
| International | 2,112,678 | 34.3% | 1,532,292 | 32.3% |
| Total Product Sales | $6,150,984 | 100.0% | $4,741,976 | 100.0% |

We achieved gross profit margin of 63% and 60% for the three and nine months ended September 30, 2009, respectively. However, our revenues and related gross profits have not been sufficient to support our overhead, new product introduction and research and development expenses. Although we anticipate expending funds for research and development in 2009, these amounts will vary based on the operating results for each quarter. We have incurred operating losses and negative cash flows from operating activities since its inception. The Company is actively pursuing the generation of positive cash flows from operating activities through increases in revenue, assessment of current contracts and current negotiations and reductions in operating expenses. At September 30, 2009, we expect to have sufficient cash reserves to meet all of our anticipated obligations through December 31, 2009.

### New Product Development and Commercialization Utilizing CompuFlo Technology

Over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. According to market research firm Business Insights, “The global market grew from $15 billion to $40 billion during 2000–2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues.” Moreover, industry analysts agree that as patients live longer and are diagnosed with chronic and often debilitating ailments, the result will be a dramatic increase in self-administration of drug therapies in non-traditional settings for a number of conditions. This trend is creating an increased interest in routes of administration that are patient-friendly and cost-effective. It appears that pharma company decision makers are realizing that new drug product success no longer only depends on the medication itself, but also on achieving a patient-friendly form of delivery.

In keeping with our stated goal for leveraging our patented *CompuFlo* technology in new medical applications, our management team has continued to identify and pursue opportunities to form strategic collaborations in the areas of self-administered drug delivery, injections for osteoarthritis pain management and epidurals. The response to our proprietary technology with whom we have engaged in meaningful teaming discussions has continued to be encouraging. Throughout 2008, we have met with healthcare companies who expressed interest in potential applications of the *CompuFlo* technology. As we progress through 2009, the Company maintains its pursuit of *CompuFlo*-based product development prospects that are deemed the most promising and commercially viable, and offer the greatest potential for allowing us to fully realize the product development and commercialization opportunities.

### Executive Management Change

On March 27, 2009, we accepted the resignation of our Chief Executive Officer, who chose to leave Milestone to pursue a new career opportunity. Our Chairman of the Board, Leonard Osser, temporarily assumed the post of Chief Executive Officer. However, on September 1, 2009, Leslie Bernhard, an independent member of our Board of Directors, was named Chairman, succeeding Mr. Osser who had led the Company as its Chairman since 1991. Mr. Osser now serves as our Chief Executive Officer.

### Technology Rights

The technology underlying our *SafetyWand* and *CompuFlo* technology and an improvement to the controls for *CompuDent* were developed by our Director of Clinical Affairs and assigned to us. We purchased this technology pursuant to an agreement dated January 1, 2005 for 43,424 shares of restricted common stock and $145,000 in cash, paid on April 1, 2005. In addition, our Director of Clinical Affairs will receive additional contingent payments of 2.5% of our total sales of *CompuDent* and Wand Plus units using some of these technologies, and 5% of our total sales of *STA* units and hand pieces using some of our other technologies. If products produced by third parties use any of these technologies, under a license from Milestone, then he will also receive the corresponding percentage of the consideration received by us for such sale or license.

### Intellectual Property

In August 2009, we were issued a Notice of Allowance by the U.S. Patent and Trademark Office for its U.S. patent application directed to the use of its disposable hand piece for fluid administration. Our award-winning hand piece is an instrument currently utilized in conjunction with the Company’s *STA, CompuDent* and *CompuMed* systems.

Subsequent to the end of the third quarter of 2009, the U.S. Patent and Trademark Office issued a Notice of Allowance for our U.S. patent application, titled “Computer Controlled Drug Delivery System with Dynamic Pressure Sensing.” This intellectual property represents one of the key technological components of our product development strategy relating to the development of advanced computer-controlled injection products for specific applications in the medical industry — most notably intra-articular injections and epidurals.

To date, we have been awarded a total of 23 U.S. utility and design patents relating to our Computer-Controlled Local Anesthesia Delivery (C-CLAD) technologies.

### Summary of Significant Accounting Policies, Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to accounts receivable, inventories, stock-based compensation, and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.

#### Accounts Receivable

The realization of Accounts Receivable will have a significant impact on the Company. Consequently, we estimate losses resulting from the inability of its customers to make payments for amounts billed. The collectability of outstanding amounts is continually assessed.

#### Inventories

Inventory costing, obsolescence and physical control are significantly important to the on-going operation of the business. Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales.

#### Impairment of Long-Lived Assets

The long-lived assets, principally patents and trademarks, are the base features of the business. We review long-lived assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The carrying value of the asset is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets.

#### Revenue Recognition

Revenue from product sales is recognized net of discounts and allowances to our domestic distributors on the date of arrival of the goods at the customer’s location as shipments are FOB destination. Shipments to our international distributor are FOB our warehouse and revenue is therefore recognized on shipment. In both cases the price to the buyer is fixed and the collectability is reasonably assured. Further, we have no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Customer acceptance is considered made at delivery. Our only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.

### Results of Operations

The consolidated results of operations for the three and nine months ended September 30, 2009 compared to the same three and nine month period in 2008 reflect our focus and development on the *STA System*, as well as our continuing efforts on identifying collaborative partners for new product development utilizing our *CompuFlo* technology.

The following table sets forth for the periods presented statement of operations data as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results.

|  | Three Months Ended September 30, 2009 |  | 2008 |  | Nine Months Ended September 30, 2009 |  | 2008 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Products sales, net | $1,909,263 | 100% | $1,813,103 | 100% | $6,150,984 | 100% | $4,741,976 | 99% |
| Royalty income | — | 0% | 5,112 | 0% | — | 0% | 28,282 | 1% |
| Total revenue | 1,909,263 | 100% | 1,818,215 | 100% | 6,150,984 | 100% | 4,770,258 | 100% |
| Cost of products sold | 709,003 | 37% | 740,398 | 41% | 2,488,294 | 40% | 1,798,758 | 38% |
| Gross Profit | 1,200,260 | 63% | 1,077,817 | 59% | 3,662,690 | 60% | 2,971,500 | 62% |
| Selling, general and administrative expenses | 1,477,948 | 77% | 1,199,353 | 66% | 4,960,000 | 81% | 4,039,137 | 85% |
| Research and development expenses | 57,972 | 3% | 35,181 | 2% | 157,941 | 3% | 119,500 | 3% |
| Total operating expenses | 1,535,920 | 80% | 1,234,534 | 68% | 5,117,941 | 83% | 4,158,637 | 88% |
| Loss from operations | (335,660) | -18% | (156,717) | -9% | (1,455,251) | -24% | (1,187,137) | -25% |
| Other income — interest & expense | (37,610) | -2% | (30,016) | -2% | (136,203) | -2% | (88,598) | -2% |
| Net loss | $(373,270) | -20% | $(186,733) | -11% | $(1,591,454) | -26% | $(1,275,735) | -27% |

20

### Three months ended September 30, 2009 compared to three months ended September 30, 2008

Total revenues for the three months ended September 30, 2009 and 2008 were $1,909,263 and $1,818,215, respectively. The total increase in product sales of $96,160, or 5%, in 2009 over 2008 is primarily the result of the continued *STA* product sales growth. Domestic *STA* unit sales decreased $75,333 in 2009 over 2008. This decrease represented a slower sell through of the *STA System* during the summer of this year. In the domestic market, hand piece sales were lower, decreasing by $77,105 or 8.2%. On the international front, unit sales increased in the third quarter of 2009 over 2008 by $115,088, or 87%, principally due to increased market penetration for the *STA System*. Internationally, hand pieces increased by $152,706, or 43% due to an increased demand. Our international business is an area of growth potential for us.

Cost of products sold for the three months ended September 30, 2009 and 2008 were $709,003 and $740,398 respectively. The $31,395, or 4%, decrease is primarily attributable to a change in sales mix.

For the three months ended September 30, 2009, we generated a gross profit of $1,200,260, or 63%, as compared to a gross profit of $1,077,817, or 59%, for the three months ended September 30, 2008. The total increase in gross profit dollars of $122,443 is due to an increase in sales dollar volume attributable to a change in our international sales process. Effective July 1, 2009, we began selling our products directly to international distributors. As a result of this change, we recorded a higher selling price of the product to our international distributor and pay a commission to our former master international distributor based on our agreement. This commission for the quarter is $117,790 and is included in Selling, General and Administrative Expenses in the third quarter.

Selling, general and administrative expenses for the three months ended September 30, 2009 and 2008 were $1,477,948 and $1,199,353, respectively. The $278,595, or 23%, increase is described in the following sections of this paragraph. Although we continue to focus on reducing expenses, the 2009 third quarter increase was due to higher expenses relating to promoting continued sales growth and increased consulting expenses. Personnel and related expenses remained relatively unchanged. Marketing ($133,053) and sales ($195,430) expenses increased principally due to increased attendance at trade shows and various sales promotions. Sales and trade show expenses increased by $18,798, as we increase participation and presence at trade shows. Additionally, international sales commission increased by $117,790 due to a change in our international sales agreement with our former master international distributor, while our third party sales representative commissions decreased based on decreased domestic sales of the *STA Systems*. Other variable sales expenses for the *STA System* and hand pieces increased in the third quarter of 2009 due to higher royalty payments ($75,058). On the positive side of the ledger, professional services decreased by $20,715 in the third quarter of 2009 over the same period in 2008. However, there was a significant increase in consulting services of $201,284 in the third quarter of 2009, paid in stock, to professionals that have assisted in our continuous growth.

Research and development expenses for the three months ended September 30, 2009 and 2008 were $57,972 and $35,181, respectively. This increase is due to expenses related to new prototype equipment in the medical field.

The loss from operations for the three months ended September 30, 2009 and 2008 was $335,660 and $156,717, respectively. The $178,943 increase in loss from operations is explained above.

Interest expense was $30,230 and amortization of debt issuance relating to the line of credit and long term note payable was $7,875 for the third quarter of 2009 compared to interest expense of $23,863 and amortization of debt issuance expense of $7,926 for the same quarter in 2008. The increase in interest expense of $6,367 is due to the $450,000 long term note, initiated in the fourth quarter of 2008 (as discussed in Note 5).

For the reasons explained above, net loss for the three months ended September 30, 2009 was $373,270 as compared to a net loss of $186,733 for the three months ended September 30, 2008. The $186,537 increase in net loss is primarily a result of the increase in sales and gross margin dollars, offset by increases in market and sales costs and an increase in consulting and other selling, general and administrative expenses.

### Nine months ended September 30, 2009 compared to the nine months ended September 30, 2008

Total revenues for the nine months ended September 30, 2009 and 2008 were $6,150,984 and $4,770,258, respectively. Total revenues increased by $1,380,726 or 29%. Contributing to this increase was *STA* unit sales of $1,268,728 and an increase in *STA* hand piece sales of $434,451. *CompuDent* unit sales remained relatively unchanged and *CompuDent* hand piece sales decreased by $333,782. The breakdown of the change is as follows. International revenue increased $580,386, or 38%, as compared to the 2008 period. Domestic product revenue increased by $828,622 in 2009, or 26%, as a result of a change in our distribution business model to a non-exclusive distributor base. This change was initiated in the second quarter of 2008. Domestic disposable hand piece sales decreased $83,721 and international disposable hand piece sales increased $211,834 or 19%. International unit sales increased by $369,534 or 87% for the nine months ending September 30, 2009 as compared to the same period in 2008. Our international business continues to be a substantial growth area for us.

Gross profit for the nine months ended September 30, 2009 and 2008 was $3,662,690, or 60%, (net of a write-down of returned defective merchandise of $36,066) and $2,971,500 or 62%, respectively. Gross profit dollars increased by $691,190 due to an increase in sales volume in 2009 over 2008. The gross profit percentage decrease was due principally to the change in product mix with a substantially larger proportion of *STA* unit sales and the write down of legacy returned defective merchandise in the nine months of 2009 over the same period in 2008. A portion of the increase in gross profit dollars ($117,790) is due to an increase in sales volume attributable to a change in how we record international sales. Effective July 1, 2009, the Company began selling our products directly to international distributors. As a result of this change, the Company records a higher selling price of the product to our international distributor and pays a commission to our former master international distributor based on our agreement. This commission is included in Selling, General and Administrative Expenses.

Selling, general and administrative expenses for the nine months ended September 30, 2009 and 2008 were $4,960,000 and $4,039,137, respectively. The increase of $920,863, or 23%, is primarily attributable to an increase in several expense categories. Sales and marketing expense increased by $614,654 for the period ending September 30, 2009. This increase was due to media and production spending of $145,281; trade shows and travel expense of $162,977; and cost relating to the C-CLAD Symposium, Key Opinion Leaders and sales promotions of $187,560, offset by savings in employee relocation of $23,869 and printing cost of $46,102. Commission expense increased by $49,703 for third party sales representatives due to sales volume increases and by $117,790 for international sales commissions (effective July 1, 2009). General and administrative expenses increased a net of $306,209. Expense increases in this category were consulting expenses of $108,103 paid in stock to professionals that have assisted in the growth of the Company, patent annuity expenses of $39,970, royalties of $155,560 (based on increased *STA* unit and hand piece sales), a business consultant study of $150,000, and an international business consultant of $39,068. On a positive note, we reduced expenses for accounting costs by $97,397 (audit, review and Sarbanes-Oxley), proxy costs by $23,516 (electronic filing, Notice and Access System), warehousing fees by $21,206 and reduced insurance costs by $29,531.

Research and development expenses for the nine months ended September 30, 2009 and 2008 were $157,941 and $119,500, respectively.

Interest expense totaled $115,619 as of September 30, 2009, an increase of $42,164, or 57%, over the same period in 2008. The increase in this expense is due to the $450,000 long term note that was initiated in the fourth quarter of 2008. Amortization of debt issuance costs of $23,625 is related to the long term debt outstanding as of September 30, 2009 (as discussed in Note 5).

For the reasons explained above, net loss for the nine months ended September 30, 2009 of $1,591,454 increased by $315,719 or 25%, over the net loss for the nine month period ended September 30, 2008.

Working capital as of September 30, 2009 is negative $406,968. Current assets declined by $573,145 in all current asset categories (principally in cash, accounts receivable and advances to a contract manufacturer) from December 31, 2008. Current liabilities increased by $1,366,511, principally due to the classification of the $1.3 million line of credit, due June 30, 2010, as a current liability at September 30, 2009. The line of credit was classified as a long-term liability as of December 31, 2008. All borrowings and interest thereon must be repaid by June 30, 2010, and after the expiration date of the line, may be repaid by us in cash or, at its option, in shares of common stock (as discussed in Note 5). Other increases in current liabilities are accounts payable for inventory purchases and a consultant business project. We are making every effort to maintain a viable lower level of inventory and to keep control of operating costs.

### Liquidity and Capital Resources

As of September 30, 2009, we had cash and cash equivalents of $497,455 and working capital of negative $406,968 The negative working capital is due to the classification of the $1.3 million line of credit as a current liability as of September 30, 2009. All borrowings and interest thereon must be repaid by June 30, 2010, and after the expiration date of the line, may be repaid by us in cash or, at its option, in shares of common stock (as discussed in Note 5). We incurred net losses of $1,591,454 and $1,275,735 and negative cash flows from operating activities of $157,948 and $693,164 for the nine months ended September 30, 2009 and 2008, respectively.

Our working capital at September 30, 2009 was a negative $406,968 compared to a positive working capital of $1,532,688 as of December 31, 2008. The significant reduction in working capital as of September 30, 2009 is due to the classification of the $1.3 million line of credit classified as a current liability at September 30, 2009 as compared to a classification as a long term liability at December 31, 2008. All borrowings and interest thereon must be repaid by June 30, 2010 and may be repaid by us in cash or at our option in shares of common stock. Current assets decreased by $573,145, principally due to a decrease in cash by $246,210 and accounts receivable by $424,862. Inventory and stock subscription receivable increased by $281,239. Current liabilities increased by $1,366,511, principally due to the classification of the line of credit. We continue to strive to maintain a reasonable level of inventory and to keep control of operating cost.

Additionally, as of September 30, 2009, we had cash and cash equivalents of $497,455 as compared to $498,576 as of June 30, 2009, a decrease of $1,121. Our working capital on June 30, 2009 as compared to September 30, 2009 improved by $167,418. This continued effort is well under way to provide a cash flow neutral position in the future.

For the nine months ended September 30, 2009, our net cash used in operating activities was $157,948. This was attributable primarily to a net loss of $1,591,454 adjusted for noncash items of $905,869, which was comprised principally of common stock and options issued for compensation and consulting services and changes in operating assets and liabilities of $527,637.

For the nine months ended September 30, 2009, we used $113,262 in investing activities. This was primarily attributable to $76,986 of legal fees related to new patent applications. We have capital expenditures of $36,276, primarily for the purchase of trade show booths for the purpose of showcasing the *STA System.*

For the nine months ended September 30, 2009, we received $25,000 in financing activities.

We have incurred operating losses and negative cash flows from operating activities since its inception. We are actively pursuing the generation of positive cash flows from operating activities through an increase in revenue based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses. The Company, at September 30, 2009, expects to have sufficient cash reserves to meet all of its anticipated obligations through December 31, 2009. If we are unable to generate positive cash flows from its operating activities it will need to raise additional capital. There is no assurance that we will be able to achieve positive operating cash flows or that traditional capital can be raised on terms and conditions satisfactory to the Company. If additional capital is required and cannot be raised, then we would be forced to curtail its development activities, reduce marketing expenses for existing dental products or adopt other cost saving measures, any of which might negatively affect the our operating results.

Our recurring losses and negative operating cash flows raised substantial doubt about its ability to continue as a going concern. The accompanying financial statements do not include any adjustment that might result from the outcome of this uncertainty.

## Controls and procedures

As filed, 1,204 characters.

Our management, including the Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of September 30, 2009 are effective to ensure that information required to be disclosed in the reports we filed or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding disclosure.

There were no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during our last fiscal quarter that have materially affected, or that are reasonably likely to materially affect, our internal controls over financial reporting.

## Risk factors

As filed, 2,766 characters.

The following factors may affect the growth and profitability of Milestone and should be considered by any prospective purchaser or current holder of our securities:

**We have no history of profitable operations. Continuing losses could exhaust our capital resources and force us to discontinue operations.**

For the nine months ended September 30, 2009 and 2008 our revenues were approximately $6.2 million and $4.8 million, respectively. In addition, we have had losses for each year since the commencement of operations, including net losses of approximately $1.7 million and $1.3 million for the nine months ended September 30, 2009 and 2008, respectively. At September 30, 2009, we had an accumulated deficit of approximately $58.9 million. At September 30, 2009, we had cash and cash equivalents $497,455 and working capital of a negative $406,968. Additionally, we secured a line of credit in the aggregate amount of $1.3 million from a stockholder. This line of credit of $1.3 million is classified as a current liability as of September 30, 2009. All borrowings and interest thereon must be repaid by June 30, 2010, and after the expiration date of the line, may be repaid by us in cash or, at its option, in shares of common stock (as discussed in Note 5). Additionally, the Company borrowed $450,000 in 2008 from the same shareholder, with an original due date of January 2009. This additional borrowing was refinanced at December 31, 2008 and the due date was extended to June 30, 2012, as discussed in Note 5. At September 30, 2009, we expect to have sufficient cash reserves to meet all of its anticipated obligations through December 31, 2009. Additionally, we are actively pursuing the generation of positive cash flows from operating activities through increases in revenues based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses. If we are unable to generate positive cash flows from its operating activities it will need to raise additional capital. There is no assurance that we will be able to achieve positive operating cash flows or that additional capital can be raised on the terms and conditions satisfactory to us if at all. If additional capital is required and it cannot be raised, then we would be forced to curtail its development activities, reduce marketing expenses for existing dental products or adopt other cost savings measures, any of which might negatively affect the our operating results.

Our recurring losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern.

There are no other changes to our risk factors from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2008.

Filed Nov 12, 2009.
Source: SEC EDGAR, the filing index for accession 0000950123-09-061578. Last ingested by Listed: Nov 14, 2026, 11:14 ET. No prices; not investment advice.
